Adaptive Pharmacogenomics, LLC

Clinical development for personalized medicine

Saturday, May 19, 2012 | 6:47 PM

Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.

Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.

Clin Pharmacol Ther. 2010 Dec;88(6):757-9

Authors: Carleton B

Interpretable and meaningful pharmacogenetic data are dependent on accurate characterization of phenotypes. High-quality reports are critical, and important clinical data must not be omitted. Adequate funding to fully support dedicated program personnel is essential to meet this requirement because an "employee-driven" network that funds its surveillance clinicians is likely to be more effective than a voluntary surveillance model in capturing both adequate numbers of cases and well-characterized clinical data for rigorous phenotyping.

PMID: 21081946 [PubMed - indexed for MEDLINE]

Dec 17, 2010 03:23 AMwww.ncbi.nlm.nih.gov
© 2008 — 2012 Adaptive Pharmacogenomics, LLC